BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

Core Insights - BriaCell Therapeutics Corp. is advancing its Phase 3 clinical study for Bria-IMT in metastatic breast cancer, having screened over 230 patients and enrolled over 160, with topline data expected in the first half of 2026 [1][9]. Group 1: Clinical Study Details - The pivotal Phase 3 study evaluates Bria-IMT combined with an immune checkpoint inhibitor against physician's choice therapy in advanced metastatic breast cancer [2][4]. - An interim analysis will occur once 144 patient events (deaths) are recorded, focusing on overall survival as the primary endpoint [5][9]. - The study has received FDA Fast Track designation, which may expedite the approval process for Bria-IMT if positive results are obtained [5][9]. Group 2: Company Statements and Expectations - Dr. William V. Williams, President & CEO, highlighted the strong engagement from clinical sites and patient interest, indicating that enrollment has exceeded expectations [3][9]. - The company is committed to sharing Phase 3 data with the U.S. FDA in the coming months, aiming to provide hope to patients with metastatic breast cancer [3][9].